CLRB

Cellectar Biosciences, Inc. (ticker: CLRB) is an NASDAQ-listed pharma company. DredgeCap's structured extraction of CLRB's SEC filings surfaces 7 active risk signals, including 4 late-filing signals, 2 delisting/deregistration signals, and 1 auditor-change signal. CLRB reported no tagged revenue in revenue and -$5.65M for the period ending 2026-03-31, with operating cash flow of -$4.85M. Cash and equivalents stood at $8.35M (down 40% year-over-year). Total assets of $11.12M exceed total liabilities of $6.40M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.